• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT VASCULAR ACCUNET EMBOLIC PROTECTION SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT VASCULAR ACCUNET EMBOLIC PROTECTION SYSTEM Back to Search Results
Catalog Number UNK RX ACCUNET
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Stroke/CVA (1770); Transient Ischemic Attack (2109); Stenosis (2263); Obstruction/Occlusion (2422)
Event Date 06/01/2015
Event Type  Injury  
Manufacturer Narrative
Estimated date of event.The unique device identifier (udi) is unknown because the part and lot number were not provided.The device was not returned for evaluation.A review of the lot history record of the reported lot could not be conducted because the part and lot number were not provided.The reported patient effects of stenosis, cerebrovascular accident and occlusion are listed in the rx accunet embolic protection system instructions for use as known patient effects associated with the use of this device.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.However, the treatment appears to be related to the operational context of the procedure.There is no indication of a product quality issue with respect to manufacture, design or labeling of the device.The acculink and viatrac devices referenced are being filed under separate medwatch mfr numbers.Attached article, titled "impact of cerebral blood perfusion and cognitive function of carotid artery stenting combined with medical therapy for patients with severe internal carotid stenosis."na.
 
Event Description
It was reported through a research article identifying that the accunet embolic system, acculink stent and viatrac balloon may be related to the following: occlusion, restenosis, cerebral ischemic stroke, transient ischemic attack, medication, and rehospitalization.This article summarizes clinical outcomes of 62 patients that were treated with an accunet filter, acculink stent and viatrac balloon.Details are listed in the attached article, titled "impact of cerebral blood perfusion and cognitive function of carotid artery stenting combined with medical therapy for patients with severe internal carotid stenosis.".
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ACCUNET EMBOLIC PROTECTION SYSTEM
Type of Device
EMBOLIC PROTECTION SYSTEM
Manufacturer (Section D)
ABBOTT VASCULAR
26531 ynez rd.
temecula CA 92591 4628
Manufacturer (Section G)
ABBOTT VASCULAR, REG # 2024168
26531 ynez road
temecula CA 92591 4628
Manufacturer Contact
lindsey bell
26531 ynez rd.
temecula, CA 92591-4628
9519143996
MDR Report Key12350158
MDR Text Key267558632
Report Number2024168-2021-07358
Device Sequence Number1
Product Code NTE
Combination Product (y/n)N
Reporter Country CodeCH
PMA/PMN Number
K081549
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type literature
Reporter Occupation Physician
Type of Report Initial
Report Date 08/20/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberUNK RX ACCUNET
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 08/11/2021
Initial Date FDA Received08/20/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Treatment
ACCULINK STENT; VIATRAC BALLOON
Patient Outcome(s) Hospitalization; Required Intervention; Disability;
Patient Age65 YR
-
-